|
1
|
Weigelt B, Peterse JL and van't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: From dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Otranto M, Sarrazy V, Bonté F, Hinz B,
Gabbiani G and Desmoulière A: The role of the myofibroblast in
tumor stroma remodeling. Cell Adhes Migr. 6:203–219. 2012.
View Article : Google Scholar
|
|
6
|
Mao Y, Keller ET, Garfield DH, Shen K and
Wang J: Stromal cells in tumor microenvironment and breast cancer.
Cancer Metastasis Rev. 32:303–315. 2013. View Article : Google Scholar
|
|
7
|
Geiger B, Bershadsky A, Pankov R and
Yamada KM: Transmembrane crosstalk between the extracellular matrix
- cytoskeleton crosstalk. Nat Rev Mol Cell Biol. 2:793–805. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Discher DE, Janmey P and Wang YL: Tissue
cells feel and respond to the stiffness of their substrate.
Science. 310:1139–1143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Engler AJ, Sen S, Sweeney HL and Discher
DE: Matrix elasticity directs stem cell lineage specification.
Cell. 126:677–689. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roberts DD: Emerging functions of
matricellular proteins. Cell Mol Life Sci. 68:3133–3136. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chiodoni C, Colombo MP and Sangaletti S:
Matricellular proteins: From homeostasis to inflammation, cancer,
and metastasis. Cancer Metastasis Rev. 29:295–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brown LF, Berse B, Van de Water L,
Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF and
Senger DR: Expression and distribution of osteopontin in human
tissues: Widespread association with luminal epithelial surfaces.
Mol Biol Cell. 3:1169–1180. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rangaswami H, Bulbule A and Kundu GC:
Osteopontin: Role in cell signaling and cancer progression. Trends
Cell Biol. 16:79–87. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anborgh PH, Mutrie JC, Tuck AB and
Chambers AF: Role of the metastasis-promoting protein osteopontin
in the tumour microenvironment. J Cell Mol Med. 14:2037–2044. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tuck AB, Arsenault DM, O'Malley FP, Hota
C, Ling MC, Wilson SM and Chambers AF: Osteopontin induces
increased invasiveness and plasminogen activator expression of
human mammary epithelial cells. Oncogene. 18:4237–4246. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin YH and Yang-Yen HF: The
osteopontin-CD44 survival signal involves activation of the
phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem.
276:46024–46030. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Philip S, Bulbule A and Kundu GC:
Osteopontin stimulates tumor growth and activation of promatrix
metalloproteinase-2 through nuclear factor-kappa B-mediated
induction of membrane type 1 matrix metalloproteinase in murine
melanoma cells. J Biol Chem. 276:44926–44935. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leali D, Dell'Era P, Stabile H, Sennino B,
Chambers AF, Naldini A, Sozzani S, Nico B, Ribatti D and Presta M:
Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in
angiogenesis. J Immunol. 171:1085–1093. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Furger KA, Menon RK, Tuck AB, Bramwell VH
and Chambers AF: The functional and clinical roles of osteopontin
in cancer and metastasis. Curr Mol Med. 1:621–632. 2001. View Article : Google Scholar
|
|
20
|
Kikuchi H, Saito Y, Sekiya J, Okano Y,
Saito M, Nakahata N, Kubohara Y and Oshima Y: Isolation and
synthesis of a new aromatic compound, brefelamide, from
dictyostelium cellular slime molds and its inhibitory effect on the
proliferation of astrocytoma cells. J Org Chem. 70:8854–8858. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Honma S, Saito M, Kikuchi H, Saito Y,
Oshima Y, Nakahata N and Yoshida M: A reduction of epidermal growth
factor receptor is involved in brefelamide-induced inhibition of
phosphorylation of ERK in human astrocytoma cells. Eur J Pharmacol.
616:38–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Yamada O, Matsushita Y,
Chagan-Yasutan H and Hattori T: Transactivation of human
osteopontin promoter by human T-cell leukemia virus type 1-encoded
Tax protein. Leuk Res. 34:763–768. 2010. View Article : Google Scholar
|
|
23
|
Zhang J, Yamada O, Kida S, Matsushita Y
and Hattori T: Down-regulation of osteopontin mediates a novel
mechanism underlying the cytostatic activity of TGF-β. Cell Oncol
(Dordr). 39:119–128. 2016. View Article : Google Scholar
|
|
24
|
Zhang J, Yamada O, Sakamoto T, Yoshida H,
Iwai T, Matsushita Y, Shimamura H, Araki H and Shimotohno K:
Down-regulation of viral replication by adenoviral-mediated
expression of siRNA against cellular cofactors for hepatitis C
virus. Virology. 320:135–143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang
J, Perry SR, Labrot ES, Wu X, Lis R, et al: SMAD4-dependent barrier
constrains prostate cancer growth and metastatic progression.
Nature. 470:269–273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boissy P, Andersen TL, Abdallah BM, Kassem
M, Plesner T and Delaissé JM: Resveratrol inhibits myeloma cell
growth, prevents osteoclast formation, and promotes osteoblast
differentiation. Cancer Res. 65:9943–9952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chakraborty G, Jain S, Patil TV and Kundu
GC: Down-regulation of osteopontin attenuates breast tumour
progression in vivo. J Cell Mol Med. 12(6A): 2305–2318. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J,
Li K, Tong X, Dai J, Yao S, et al: Down-regulation of osteopontin
suppresses growth and metastasis of hepatocellular carcinoma via
induction of apoptosis. Gastroenterology. 135:956–968. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mi Z, Guo H, Russell MB, Liu Y, Sullenger
BA and Kuo PC: RNA aptamer blockade of osteopontin inhibits growth
and metastasis of MDA-MB231 breast cancer cells. Mol Ther.
17:153–161. 2009. View Article : Google Scholar
|
|
30
|
Hijiya N, Setoguchi M, Matsuura K, Higuchi
Y, Akizuki S and Yamamoto S: Cloning and characterization of the
human osteopontin gene and its promoter. Biochem J. 303:255–262.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang D, Yamamoto S, Hijiya N, Benveniste
EN and Gladson CL: Transcriptional regulation of the human
osteopontin promoter: Functional analysis and DNA-protein
interactions. Oncogene. 19:5801–5809. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim HJ, Lee MH, Park HS, Park MH, Lee SW,
Kim SY, Choi JY, Shin HI, Kim HJ and Ryoo HM: Erk pathway and
activator protein 1 play crucial roles in FGF2-stimulated premature
cranial suture closure. Dev Dyn. 227:335–346. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Joseph EW, Pratilas CA, Poulikakos PI,
Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A,
et al: The RAF inhibitor PLX4032 inhibits ERK signaling and tumor
cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad
Sci USA. 107:14903–14908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Demagny H, Araki T and De Robertis EM: The
tumor suppressor Smad4/DPC4 is regulated by phosphorylations that
integrate FGF, Wnt, and TGF-β signaling. Cell Reports. 9:688–700.
2014. View Article : Google Scholar
|
|
35
|
Alazzouzi H, Alhopuro P, Salovaara R,
Sammalkorpi H, Järvinen H, Mecklin JP, Hemminki A, Schwartz S Jr,
Aaltonen LA and Arango D: SMAD4 as a prognostic marker in
colorectal cancer. Clin Cancer Res. 11:2606–2611. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peng B, Fleming JB, Breslin T, Grau AM,
Fojioka S, Abbruzzese JL, Evans DB, Ayers D, Wathen K, Wu T, et al:
Suppression of tumorigenesis and induction of p15(ink4b) by
Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res.
8:3628–3638. 2002.PubMed/NCBI
|
|
37
|
Zhang B, Halder SK, Kashikar ND, Cho YJ,
Datta A, Gorden DL and Datta PK: Antimetastatic role of Smad4
signaling in colorectal cancer. Gastroenterology. 138:969–980.
2010. View Article : Google Scholar
|
|
38
|
Tian X, Du H, Fu X, Li K, Li A and Zhang
Y: Smad4 restoration leads to a suppression of Wnt/beta-catenin
signaling activity and migration capacity in human colon carcinoma
cells. Biochem Biophys Res Commun. 380:478–483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Duda DG, Sunamura M, Lefter LP, Furukawa
T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, et al:
Restoration of SMAD4 by gene therapy reverses the invasive
phenotype in pancreatic adenocarcinoma cells. Oncogene.
22:6857–6864. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tajima K, Ohashi R, Sekido Y, Hida T, Nara
T, Hashimoto M, Iwakami S, Minakata K, Yae T, Takahashi F, et al:
Osteopontin-mediated enhanced hyaluronan binding induces multidrug
resistance in mesothelioma cells. Oncogene. 29:1941–1951. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pang H, Cai L, Yang Y, Chen X, Sui G and
Zhao C: Knockdown of osteopontin chemosensitizes MDA-MB-231 cells
to cyclo-phosphamide by enhancing apoptosis through activating p38
MAPK pathway. Cancer Biother Radiopharm. 26:165–173. 2011.
View Article : Google Scholar : PubMed/NCBI
|
